Clinical Trials Logo

Clinical Trial Summary

Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, we aim to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05038358
Study type Observational
Source University Hospital, Grenoble
Contact GAEL ROTH, MD, PHD
Phone 04 76 76 51 68
Email [email protected]
Status Not yet recruiting
Phase
Start date September 30, 2021
Completion date September 30, 2026